According to the unnamed sources, MN Pharmaceuticals could be valued at USD1bn (EUR761m). The company's owners, the family of its founder, Mustafa Nevzat Pisak, are seeking a price of between 15 and 20 times its EBITDA, the sources said on condition of anonymity.
BofA Merrill Lynch is acting as advisor on the sale, whose first round is likely to be completed within two months, the informed people said.
Potential bidders also include US Mylan Inc (NASDAQ:MYL) and Abbott Laboratories (NYSE:ABT).
None of the involved parties provided comment on the report.
MN Pharmaceuticals, with annual sales of about USD250m, is the first Turkish company to receive the US Food and Drug Administration's (FDA) go-ahead to market its products in the United States. MN Pharmaceuticals' portfolio encompasses various drugs including antidepressants, diabetic drugs and antipsychotic agents.
(USD1 = EUR0.761)
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Dexcel Pharma's Nintedanib Capsules approved for US launch
Upsher-Smith launches generic version of Ciprodex ear drop suspension
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
Arna Pharma signs MOU with Slate Run Pharmaceuticals
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz